India markets closed
  • BSE SENSEX

    52,975.80
    +138.59 (+0.26%)
     
  • Nifty 50

    15,856.05
    +32.00 (+0.20%)
     
  • USD/INR

    74.4250
    -0.0250 (-0.03%)
     
  • Dow

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • BTC-INR

    2,543,989.50
    +27,557.25 (+1.10%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • Hang Seng

    27,321.98
    -401.86 (-1.45%)
     
  • Nikkei

    27,548.00
    +159.80 (+0.58%)
     
  • EUR/INR

    87.6338
    -0.0146 (-0.02%)
     
  • GBP/INR

    102.3076
    -0.1833 (-0.18%)
     
  • AED/INR

    20.2200
    -0.0050 (-0.02%)
     
  • INR/JPY

    1.4824
    +0.0055 (+0.37%)
     
  • SGD/INR

    54.7280
    -0.0460 (-0.08%)
     

Glenmark Life IPO opens on 27 July; check price band, other details here

·1-min read

The initial public offering (IPO) for Glenmark Life Sciences will open on 27 July. The company has also announced the price band at Rs 695-720 per equity. The IPO will be the issuance of fresh equity of Rs 1,060 crore and an offer for sale (OFS) of 6.3 lakh shares from the parent company, Glenmark Pharma who has a 100 percent stake in Glenmark Life Sciences.

The subscription will end on 29 July and the shares of the company will be listed on both the BSE and NSE.

Qualified institutional buyers will have the first choice on half of the total issue, 35 percent of equity shares have been reserved for retail investors, and the remaining 15 percent for non-institutional investors. The company will be looking to raise up to Rs 1,513.6 crore, a significant portion of which will go towards reducing the debt burden on Glenmark Pharma.

It is reported that Rs 900 crore will be given to Glenmark Pharma and Rs 152.76 crore will fund Glenmark Life Science's capital expenditure requirements.

The reports of the IPO had first surfaced in June.

Glenmark Life Sciences is the active pharmaceutical ingredient arm of Glenmark Pharma, responsible for manufacturing key ingredients required in other drugs and medicines.

The company already counted 120 products in its portfolio in December and planned to expand beyond Europe, North America, Latin America, and Japan.

Also See: Glenmark Pharma on roll, hits new 52-week high on spate of recent approvals

Glenmark, Particle Sciences enter deal to develop generic cancer drug

Glenmark gets favourable interim award against Napo Pharma

Read more on Business by Firstpost.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting